1704699-99-9
Chemical Structure
IBR120
- CAS No.: 1704699-99-9
- Formula:C23H20N2O2S
- Molecular Weight:388.48
InChIKey: WCZRIPJXOMUAPT-HSZRJFAPSA-N
SMILES: O=S(CC1=CC=CC=C1)(N2[C@@H](C3=CNC4=CC=CC=C34)C5=CC=CC=C5C2)=O
Biological Activity: IBR120 is a RAD51 inhibitor. IBR120 inhibits homologous recombination (HR) repair and attenuates RAD51-DNA interaction by binding to the hydrophobic pocket of the RAD51 core domain and disrupting RAD51 multimerization. IBR120 induces apoptotic cell death and inhibits the proliferation of a broad spectrum of cancer cell lines. IBR120 in combination with anticancer agents such as EGFR inhibitors and microtubule agents produces synergistic anti-proliferative effects. IBR120 can be used in research related to breast cancer, chronic myeloid leukemia, osteosarcoma, cervical cancer, and glioblastoma[1][2][3][4].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
IBR120 | IBR120 is a RAD51 inhibitor. IBR120 inhibits homologous recombination (HR) repair and attenuates RAD51-DNA interaction by binding to the hydrophobic pocket of the RAD51 core domain and disrupting RAD51 multimerization. IBR120 induces apoptotic cell death and inhibits the proliferation of a broad spectrum of cancer cell lines. IBR120 in combination with anticancer agents such as EGFR inhibitors and microtubule agents produces synergistic anti-proliferative effects. IBR120 can be used in research related to breast cancer, chronic myeloid leukemia, osteosarcoma, cervical cancer, and glioblastoma. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Zhu J, et al. Synthesis, molecular modeling, and biological evaluation of novel RAD51 inhibitors. European journal of medicinal chemistry. 2015;96:196-208. [Content Brief]
- [2]. Ferguson P J, Black M, Figueredo R, et al. Synergistic antiproliferative activity between anticancer drugs and RAD51 inhibitors IBR2 and IBR120[J]. Cancer Research, 2019, 79(13_Supplement): 3057-3057.
- [3]. Asan A. Nitroalkene Repression of Homologous Recombination as a Treatment for Triple Negative Breast Cancer (Doctoral dissertation, et al.
- [4]. Ferguson P J, et al. Antiproliferative activity of EC359, an inhibitor of leukemia inhibitory factor receptor (LIF-R), singly and in combination with chemotherapy drugs against pancreatic cancer cell lines[J]. Cancer Research, 2022, 82(12_Supplement): 1062-1062.
